AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing a botulinum toxin complex through a 351(k) biosimilar pathway, has announced its participation in the upcoming Leerink Global Healthcare Conference. The event will take place from March 10-12, 2025 in Miami, FL.
Marc Forth, the company's President and Chief Executive Officer, will deliver a corporate overview during the conference. Interested parties can arrange one-on-one meetings with management through their Leerink representatives.
AEON Biopharma (NYSE: AEON), un'azienda biofarmaceutica in fase clinica che sviluppa un complesso di tossina botulinica attraverso un percorso biosimilare 351(k), ha annunciato la sua partecipazione alla prossima Leerink Global Healthcare Conference. L'evento si svolgerà dal 10 al 12 marzo 2025 a Miami, FL.
Marc Forth, Presidente e Amministratore Delegato dell'azienda, presenterà una panoramica aziendale durante la conferenza. Le parti interessate possono organizzare incontri one-to-one con la direzione tramite i loro rappresentanti Leerink.
AEON Biopharma (NYSE: AEON), una empresa biofarmacéutica en etapa clínica que desarrolla un complejo de toxina botulínica a través de una vía biosimilar 351(k), ha anunciado su participación en la próxima Leerink Global Healthcare Conference. El evento se llevará a cabo del 10 al 12 de marzo de 2025 en Miami, FL.
Marc Forth, Presidente y Director Ejecutivo de la empresa, ofrecerá una visión general de la empresa durante la conferencia. Las partes interesadas pueden organizar reuniones individuales con la dirección a través de sus representantes de Leerink.
AEON Biopharma (NYSE: AEON), 임상 단계의 생물 의약품 회사로, 351(k) 바이오시밀러 경로를 통해 보툴리눔 독소 복합체를 개발하고 있으며, 다가오는 Leerink Global Healthcare Conference에 참가한다고 발표했습니다. 이 행사는 2025년 3월 10일부터 12일까지 플로리다주 마이애미에서 열릴 예정입니다.
회사의 회장 겸 CEO인 Marc Forth는 회의 중 기업 개요를 발표할 것입니다. 관심 있는 당사자는 Leerink 대표를 통해 경영진과의 일대일 회의를 조율할 수 있습니다.
AEON Biopharma (NYSE: AEON), une entreprise biopharmaceutique en phase clinique développant un complexe de toxine botulique via un chemin biosimilaire 351(k), a annoncé sa participation à la prochaine Leerink Global Healthcare Conference. L'événement se déroulera du 10 au 12 mars 2025 à Miami, FL.
Marc Forth, président et directeur général de l'entreprise, présentera un aperçu de l'entreprise lors de la conférence. Les parties intéressées peuvent organiser des réunions individuelles avec la direction par l'intermédiaire de leurs représentants Leerink.
AEON Biopharma (NYSE: AEON), ein biopharmazeutisches Unternehmen in der klinischen Phase, das einen Botulinumtoxin-Komplex über einen 351(k) Biosimilar-Pfad entwickelt, hat seine Teilnahme an der bevorstehenden Leerink Global Healthcare Conference angekündigt. Die Veranstaltung findet vom 10. bis 12. März 2025 in Miami, FL statt.
Marc Forth, Präsident und CEO des Unternehmens, wird während der Konferenz einen Unternehmensüberblick geben. Interessierte Parteien können über ihre Leerink-Vertreter Einzelgespräche mit dem Management vereinbaren.
- None.
- None.
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that Marc Forth, AEON’s President and Chief Executive Officer, will present a corporate overview at the Leerink Global Healthcare Conference being held March 10 – 12, 2025 in Miami, FL.
Leerink Global Healthcare Conference
| Format: | Corporate Presentation | |
| Date/time: | Monday, March 10 at 1:00-1:30 PM ET | |
| Location: | Miami, FL | |
If you are interested in setting up a one-on-one meeting with management during the conference, please contact your Leerink representative.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
When is AEON Biopharma presenting at the Leerink Global Healthcare Conference 2025?
What is AEON Biopharma's main product development focus?
Who will represent AEON Biopharma at the Leerink Healthcare Conference?
How can investors meet with AEON Biopharma's management at the Leerink conference?
